Corcept Therapeutics Incorporated (NASDAQ:CORT) Q2 2025 Earnings Call Transcript
Operator: Thank you for standing by, and welcome to the Corcept Therapeutics Second Quarter 2025 Earnings Conference Call.
Corcept Therapeutics Inc (CORT)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Renaissance Technologies Jim Simons | 6,266,402 | $459,953,907 | +3% | 0.61% |
| 2. | Arrowstreet Capital Peter Rathjens, Bruce Clarke And John Campbell | 788,809 | $57,898,581 | -48% | 0.04% |
| 3. | D E Shaw D. E. Shaw | 673,137 | $49,408,256 | -4% | 0.04% |
| 4. | Driehaus Capital Richard Driehaus | 481,305 | $35,327,787 | +86% | 0.28% |
| 5. | Citadel Investment Group Ken Griffin | 446,004 | $32,736,693 | +1479% | 0.01% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $21.53 | 100,000 | $2,153,000.00 | 3,308,303 | 2021-06-11 | Filing | |
| $21.53 | 50,000 | $1,076,500.00 | 1,046,838 | 2021-06-11 | Filing | |
| $22.64 | 68 | $1,539.52 | 3,208,303 | 2020-12-01 | Filing | |
| $22.80 | 1,109 | $25,285.20 | 3,208,235 | 2020-11-30 | Filing | |
| $22.81 | 361 | $8,232.79 | 3,207,126 | 2020-11-25 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $72.30 | 2,200 | $159,060.00 | 0 | 2025-08-11 | Filing | |
| $71.77 | 35,007 | $2,512,452.39 | 5,487 | 2025-08-08 | Filing | |
| $71.77 | 14 | $1,004.78 | 5,487 | 2025-08-05 | Filing | |
| $69.70 | 1,714 | $119,467.17 | 7,681 | 2025-08-01 | Filing | |
| $68.52 | 5,428 | $371,952.07 | 9,395 | 2025-08-01 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 12,530,789 | $919,759,911 | 0.02% | |
| 2. | 9,680,592 | $710,555,453 | 0.01% | |
| 3. | 3,871,123 | $284,140,428 | 5.68% | |
| 4. | 2,967,587 | $217,820,886 | 0.01% | |
| 5. | 2,085,517 | $153,077,522 | 0.04% |
News See All
H.C. Wainwright Remains Bullish on Corcept Therapeutics Incorporated (CORT)
Corcept Therapeutics Incorporated (NASDAQ:CORT) is one of the most profitable biotech stocks to invest in now. On July 14, H.C.
Corcept Therapeutics Advances Pipeline Fueling Growth With Controlled Risk
Corcept Therapeutics Incorporated (NASDAQ:CORT) is a California-based company specializing in cortisol modulation through glucocorticoid receptor antagonists.
10 Most Profitable Biotech Stocks to Invest in Now
Jared Holz, Mizuho health care equity strategist, appeared on CNBC’s 'Power Lunch' on March 5 to talk about investing in biotech and the oversaturation in the sector.
Corcept (CORT) Advances Ovarian Cancer Therapy with FDA Filing for Relacorilant
Corcept Therapeutics Incorporated (NASDAQ:CORT) is one of the growth stocks that could double by 2027.
11 Best Long Term Low Risk Stocks to Invest in
The uncertainty prevailing in the current market environment demands a closer examination beyond just earnings reports and share price trends when seeking a worthy investment.
Corcept Advances Cancer Drug as Analysts Back Strong Growth Prospects
Corcept Therapeutics Incorporated (NASDAQ:CORT) is a pharmaceutical company specializing in cortisol modulation by developing compounds that antagonize the glucocorticoid receptor.
11 Growth Stocks That Could Double by 2027
The focus should be on growth stocks over value stocks, as volatility in the equity markets has subsided significantly.
13 Best Low Risk High Growth Stocks to Buy
The current market is witnessing political chess moves, which are also affecting policy changes.
Corcept Therapeutics (CORT) Announces Pivotal Data from Phase 3 ROSELLA Trial
Corcept Therapeutics Incorporated (NASDAQ:CORT) is one of the 13 Best Pharma Stocks to Buy According to Wall Street Analysts.
Billionaire Hedge Funds
